𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma

✍ Scribed by Zahra Taheri-Kadkhoda; Bengt Magnusson; Marie Svensson; Claes Mercke; Thomas Björk-Eriksson


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
440 KB
Volume
31
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Background

We aimed to identify clinical significance of latent membrane protein 1 (LMP1), Ki‐67, cyclin‐B1, and epidermal growth factor receptor (EGFR), in nonendemic nasopharyngeal carcinoma (NPC).

Methods

The relation between expression of the markers in 45 NPC specimens and clinicopathological and survival variables was statistically analyzed.

Results

LMP1 was present in 33% of the tumors, and its presence was associated with advanced nodal and disease stages. Overexpression was defined as labeling index ≥ median value for Ki‐67, ≥ 15% for cyclin‐B1, and ≥50% for EGFR, and it was displayed in 50%, 55%, and 80% of the specimens, respectively. Strong EGFR staining intensity and not overexpression of the 3 markers was the variable with statistically significant impact on treatment outcomes in terms of worse local and locoregional tumor control rates.

Conclusions

Our results suggest that the evaluation of EGFR staining intensity in patients with NPC may identify a subgroup of patients with poor prognosis. © 2009 Wiley Periodicals, Inc. Head Neck, 2009


📜 SIMILAR VOLUMES


Prognostic significance of tumor angioge
✍ Brigette B. Y. Ma; Terence C. W. Poon; K. F. To; Benny Zee; Frankie K. F. Mo; Ch 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 2 views

## Abstract ## Background. This study prospectively examines the prognostic role of p53 oncoprotein (p53), Ki67‐antigen (Ki67), tumor angiogenesis (MVD), epidermal growth factor receptor (EGFR), and HER2 receptor protein (HER2) expression in Chinese with undifferentiated nasopharyngeal carcinoma (